US2016317683A1PendingUtilityA1

Therapeutic Agents and Uses Thereof

51
Assignee: FREDAX ABPriority: Oct 28, 2011Filed: Apr 21, 2016Published: Nov 3, 2016
Est. expiryOct 28, 2031(~5.3 yrs left)· nominal 20-yr term from priority
Inventors:Sven-Erik StrandAmanda Thuy TranSven-Niklas Anders Axelsson
A61P 35/04A61P 35/00G01N 2333/96455A61K 51/1075A61K 49/221C07K 16/3069C07K 2317/565A61P 13/08A61K 49/16A61K 51/1072A61K 51/1093C07K 16/18A61K 51/1018A61K 51/1096C07K 16/40G01N 33/57555A61K 47/6803
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.

Claims

exact text as granted — not AI-modified
1 : An agent comprising (a) an antibody or antigen-binding fragment thereof with specificity for a kallikrein protein and (b) a cytotoxic moiety. 
     
     
         2 . (canceled) 
     
     
         3 : A method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising an antibody or antigen-binding fragment thereof with specificity for a kallikrein protein. 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 : The agent according to  claim 1  wherein the kallikrein is selected from the group consisting of prostate-specific antigen (PSA; hk3, human kallikrein gene 3) and human glandular kallikrein (hK2). 
     
     
         7 : The agent according to  claim 1 , wherein the antibody or antigen-binding fragment thereof with specificity for a kallikrein protein has specificity for PSA. 
     
     
         8 - 11 . (canceled) 
     
     
         12 : The agent according to  claim 7 , wherein the antibody or antigen-binding fragment thereof with specificity for a kallikrein protein competes for binding to PSA with an antibody selected from the group consisting of PSA30, 4D4, 5C3, and 5A10. 
     
     
         13 : The agent according to  claim 12 , wherein the antibody or antigen-binding fragment thereof with specificity for a kallikrein protein comprises one or more complementarity determining regions (CDRs) of an antibody selected from the group consisting of PSA30, 4D4, 5C3, and 5A10. 
     
     
         14 . (canceled) 
     
     
         15 : The agent according to  claim 1 , wherein the antibody or antigen-binding fragment thereof with specificity for a kallikrein protein has specificity for human glandular kallikrein (hK2). 
     
     
         16 : The agent according to  claim 15 , wherein the antibody or antigen-binding fragment thereof with specificity for a kallikrein protein competes for binding to hK2 with an antibody selected from the group consisting of 11B6, and 7G1. 
     
     
         17 : The agent according to  claim 16  wherein the antibody or antigen-binding fragment thereof with specificity for a kallikrein protein comprises one or more complementarity determining regions (CDRs) of an antibody selected from the group consisting of 11B6, and 7G1. 
     
     
         18 - 21 . (canceled) 
     
     
         22 : The agent according to  claim 1 , wherein the cytotoxic moiety comprises one or more radioisotopes. 
     
     
         23 - 25 . (canceled) 
     
     
         26 : The agent according to  claim 1 , wherein the cytotoxic moiety comprises of one or more cytotoxic drugs. 
     
     
         27 - 45 . (canceled) 
     
     
         46 : A pharmaceutical composition comprising a therapeutically effective amount of an agent according to  claim 1 , and a pharmaceutically-acceptable diluent, carrier or excipient. 
     
     
         47 - 56 . (canceled) 
     
     
         57 : A method according to  claim 3  wherein the agent comprises a cytotoxic moiety. 
     
     
         58 : A method according to  claim 3  wherein the kallikrein is selected from the group consisting of prostate-specific antigen (PSA; hk3, human kallikrein gene 3) and human glandular kallikrein (hK2). 
     
     
         59 : A method according to  claim 58  wherein the kallikrein is PSA. 
     
     
         60 : A method according to  claim 58  wherein the kallikrein is hK2. 
     
     
         61 : A method according to  claim 57  wherein the cytotoxic moiety comprises one or more radioisotopes. 
     
     
         62 : A method according to  claim 57  wherein the cytotoxic moiety comprises one or more cytotoxic drugs. 
     
     
         63 : A method according to  claim 3  wherein the prostate cancer to be treated is metastatic prostate cancer, optionally micrometastatic prostate cancer. 
     
     
         64 : A method according to  claim 63  wherein the metastatic prostate cancer to be treated comprises metastases within the lymph system, bone (including spine, vertebrae, pelvis, ribs), rectum, bladder and/or urethra.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.